Humanigen logo
Humanigen HGEN

Quarterly report 2023-Q1
added 05-15-2023

report update icon

Humanigen Balance Sheet 2011-2026 | HGEN

Annual Balance Sheet Humanigen

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-45 M -67.7 M 3.14 M 1.87 M 18.6 M 1.38 M -8.43 M 5 K -44.2 M -1.12 M -3.34 M

Long Term Debt

- 25 M - 1.25 M 1.22 M 1.35 M 1.27 M - - 6.79 M 9.83 M -

Total Non Current Liabilities

- - 2.34 M 1.25 M 1.22 M 1.35 M 1.27 M 5.41 M 311 K 6.79 M 10.2 M 400 K

Total Current Liabilities

56.2 M 68.7 M 20.4 M 13.6 M 8.26 M 24.7 M 7.82 M - 18.1 M 11.4 M 7.22 M -

Total Liabilities

58 M 94.7 M 22.8 M 14.8 M 9.48 M 26 M 9.1 M 5.41 M 18.4 M 18.2 M 17.5 M 8.51 M

Deferred Revenue

883 K 4.14 M 1.87 M - - - - - - - - -

Retained Earnings

-682 M -611 M -374 M -285 M -275 M -263 M -241 M -214 M -178 M -140 M -98.3 M -74.8 M

Total Assets

11.2 M 71.1 M 68.3 M 523 K 1.37 M 1.67 M 4.72 M 11.1 M 43 M 78.7 M 24.5 M 19.4 M

Cash and Cash Equivalents

10.2 M 70 M 67.7 M 143 K 814 K 737 K 2.91 M 8.43 M 10.9 M 54.2 M 10.9 M 3.34 M

Book Value

-46.8 M -23.7 M 45.5 M -14.3 M -8.11 M -24.3 M -4.38 M 5.73 M 24.6 M 60.5 M 7.08 M 10.8 M

Total Shareholders Equity

-46.8 M -23.7 M 45.5 M -14.3 M -8.11 M -24.3 M -4.38 M 5.73 M 24.6 M 60.5 M -94.9 M -72.3 M

All numbers in USD currency

Quarterly Balance Sheet Humanigen

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - 22.5 M 25.2 M 25 M 24.8 M 24.6 M 24.4 M - - - 7.32 M 6.49 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - 2.34 M - - - 1.25 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

54.8 M 58 M 78.4 M 99.5 M 96.4 M 94.7 M 95.6 M 78 M 81.8 M 22.8 M 22.8 M 22.8 M 22.8 M 14.8 M 14.8 M 14.8 M 14.8 M 9.48 M 9.48 M 9.48 M 9.48 M 26 M 26 M 26 M 26 M 9.1 M 9.1 M 9.1 M 9.1 M 5.41 M 5.41 M 5.41 M 5.41 M 18.4 M 18.4 M 18.4 M 18.4 M 18.2 M 18.2 M 18.2 M 18.2 M 17.5 M 17.5 M 17.5 M 17.5 M 8.51 M 8.51 M 8.51 M -

Deferred Revenue

883 K 883 K 884 K 3.09 M 4.13 M 4.14 M 4.14 M 4.14 M 4.14 M 1.87 M 1.87 M 1.87 M 1.87 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 5.63 M 5.63 M 5.63 M -

Retained Earnings

-686 M -682 M -686 M -663 M -632 M -611 M -578 M -511 M -440 M -374 M -374 M -374 M -374 M -285 M -285 M -285 M -285 M -275 M -275 M -275 M -275 M -263 M -263 M -263 M -263 M -241 M -241 M -241 M -241 M -214 M -214 M -214 M -214 M -178 M -178 M -178 M -178 M -140 M -140 M -140 M -140 M -98.3 M -98.3 M -98.3 M -98.3 M -74.8 M -74.8 M -74.8 M -

Total Assets

5.12 M 11.2 M 26 M 49.4 M 71.3 M 71.1 M 77.9 M 122 M 98.8 M 68.3 M 68.3 M 68.3 M 68.3 M 523 K 523 K 523 K 523 K 1.37 M 1.37 M 1.37 M 1.37 M 1.67 M 1.67 M 1.67 M 1.67 M 4.72 M 4.72 M 4.72 M 4.72 M 11.1 M 11.1 M 11.1 M 11.1 M 43 M 43 M 43 M 43 M 78.7 M 78.7 M 78.7 M 78.7 M 24.5 M 24.5 M 24.5 M 24.5 M 19.3 M 19.3 M 19.3 M -

Cash and Cash Equivalents

3.1 M 10.2 M 24.7 M 47 M 68.9 M 70 M 76.5 M 121 M 92.9 M 67.7 M 67.7 M 67.7 M 67.7 M 143 K 143 K 143 K 143 K 814 K 814 K 814 K 814 K 737 K 737 K 737 K 737 K 3.01 M 2.91 M 2.91 M 2.91 M 8.43 M 8.43 M 8.43 M 8.43 M 10.9 M 10.9 M 10.9 M 10.9 M 54.2 M 54.2 M 54.2 M 54.2 M 10.9 M 10.9 M 10.9 M 10.9 M 3.34 M 3.34 M 3.34 M -

Book Value

-49.7 M -46.8 M -52.4 M -50.1 M -25 M -23.7 M -17.6 M 43.7 M 17 M 45.5 M 45.5 M 45.5 M 45.5 M -14.3 M -14.3 M -14.3 M -14.3 M -8.11 M -8.11 M -8.11 M -8.11 M -24.3 M -24.3 M -24.3 M -24.3 M -4.38 M -4.38 M -4.38 M -4.38 M 5.73 M 5.73 M 5.73 M 5.73 M 24.6 M 24.6 M 24.6 M 24.6 M 60.5 M 60.5 M 60.5 M 60.5 M 7.08 M 7.08 M 7.08 M 7.08 M 10.8 M 10.8 M 10.8 M -

Total Shareholders Equity

-49.7 M -46.8 M -52.4 M -50.1 M -25 M -23.7 M -17.6 M 43.7 M 17 M 45.5 M 45.5 M 45.5 M 45.5 M -14.3 M -14.3 M -14.3 M -14.3 M -8.11 M -8.11 M -8.11 M -8.11 M -24.3 M -24.3 M -24.3 M -24.3 M -4.38 M -4.38 M -4.38 M -4.38 M 5.73 M 5.73 M 5.73 M 5.73 M 24.6 M 24.6 M 24.6 M 24.6 M 60.5 M 60.5 M 60.5 M 60.5 M -94.9 M -94.9 M -94.9 M -94.9 M -72.3 M -72.3 M -72.3 M -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Humanigen, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.89 - $ 6.54 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.2 - $ 3.68 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 15.9 - $ 50.8 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.76 - $ 27.9 M israelIsrael
Exelixis Exelixis
EXEL
$ 44.69 - $ 12.1 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Galapagos NV Galapagos NV
GLPG
$ 27.86 - $ 2.69 B belgiumBelgium
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Grifols, S.A. Grifols, S.A.
GRFS
$ 7.91 - $ 6.83 B spainSpain
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 31.05 - $ 1.79 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 8.44 - $ 76.2 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 101.57 - $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Immuron Limited Immuron Limited
IMRN
$ 0.81 0.3 % $ 9.47 M australiaAustralia
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Incyte Corporation Incyte Corporation
INCY
$ 99.1 - $ 19.3 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 0.7 - $ 1.71 M canadaCanada
INmune Bio INmune Bio
INMB
$ 1.33 - $ 32.9 M usaUSA
Innoviva Innoviva
INVA
$ 23.05 - $ 1.55 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.48 -0.67 % $ 235 M franceFrance
Jaguar Health Jaguar Health
JAGX
$ 7.88 - $ 18.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
$ 26.67 - $ 1.44 B britainBritain
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.11 - $ 260 M israelIsrael
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.98 - $ 4.91 M israelIsrael
Krystal Biotech Krystal Biotech
KRYS
$ 259.95 - $ 7.52 B usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 12.42 - $ 1.65 B australiaAustralia
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 224.86 - $ 4.11 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Liquidia Corporation Liquidia Corporation
LQDA
$ 38.15 - $ 3.28 B usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.05 - $ 433 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA